Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Oncology

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

1100%

+ 1 programs with unclassified modality

Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.

$53.9B marketConsolidating→ Stable30 products15 companies

Key Trends

Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges

Career Verdict

Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	ELIQUIS (apixaban)	Bristol Myers Squibb	$18.3B	34%	Launch	Stable	15.0yr
2	FARXIGA (dapagliflozin)	AstraZeneca	$4.3B	8%	Peak	Stable	15.4yr
3	REVLIMID (lenalidomide)	Bristol Myers Squibb	$3.9B	7%	LOE Approaching	Declining	1.8yr
4	XTANDI (enzalutamide)	Astellas	$2.6B	5%	Peak	Stable	10.7yr
5	IMBRUVICA (ibrutinib)	AbbVie	$2.4B	4%	Peak	Stable	8.9yr

#1ELIQUIS

$18.3B

Bristol Myers Squibb·Launch15.0yr

#2FARXIGA

$4.3B

AstraZeneca·Peak15.4yr

#3REVLIMID

$3.9B

Bristol Myers Squibb·LOE Approaching1.8yr

#4XTANDI

$2.6B

Astellas·Peak10.7yr

#5IMBRUVICA

$2.4B

AbbVie·Peak8.9yr

Drug Class Breakdown

FXa Inhibitors

$18.3B(34%)

concentrated in single product

SGLT2 Inhibitors

$4.3B(8%)

single dominant product

Kinase Inhibitors

$4.0B(7%)

multi-product class, competitive

Immunomodulatory Agents (Cereblon)

$3.9B(7%)

facing near-term patent cliff

Androgen Receptor Antagonists

$2.6B(5%)

prostate cancer specialty

Protein Kinase Inhibitors

$2.4B(4%)

niche hematologic oncology

JAK Inhibitors

$1.9B(4%)

near-term LOE exposure

Career Outlook

Stable

Oncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.

Breaking In

Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.

For Experienced Professionals

Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.

In-Demand Skills

Regulatory strategy & PDUFA navigationKinase inhibitor development (small molecule)Clinical trial operations & site managementLifecycle management & patent strategyMedical affairs (oncology-specific science)Manufacturing scale-up (small molecule & biotech)

Best For

Regulatory Affairs ManagerClinical Operations ManagerMedical Science Liaison (MSL) — OncologyLifecycle ManagerR&D Scientist (medicinal chemistry, ADME)Manufacturing Engineer

Hiring Landscape

$102K–$266K

Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.

1,946

Open Roles

Companies Hiring

Departments

Top Hiring Companies

Thermo Fisher Scientific

559

208

185

167

147

By Department

Commercial(21%)

$136K

Research & Development(18%)

$199K

Clinical Operations(5%)

$181K

Medical Affairs(4%)

$266K

Manufacturing(5%)

$102K

Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

LaNova MedicinesChina - Shanghai

2 programs

LM-108 in combination with ToripalimabPHASE_3Monoclonal Antibody1 trial

LM-302PHASE_31 trial

Active Trials

NCT07362186Not Yet Recruiting400Est. Sep 2028

NCT06351020Active Not Recruiting387Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2024

2025

2026

2027

2028

LaNova MedicinesLM-108 in combination with Toripalimab

LaNova MedicinesLM-302

Clinical Trials (2)

Total enrollment: 787 patients across 2 trials

NCT07362186 LaNova MedicinesLM-108 in combination with Toripalimab

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Start: Apr 2026Est. completion: Sep 2028400 patients

Phase 3Not Yet Recruiting

NCT06351020 LaNova MedicinesLM-302

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Start: Jun 2024Est. completion: Dec 2026387 patients

Phase 3Active Not Recruiting

Related Jobs in Oncology

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)

1 companies competing in this space

Related Indications

Breast Cancer(1518)Non-small Cell Lung Cancer(976)Prostate Cancer(814)Multiple Myeloma(669)Cancer(668)Advanced Solid Tumors(522)Advanced Solid Tumor(465)Colorectal Cancer(464)Melanoma(462)Solid Tumor(434)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.